By King Brand Healthcare Products, manufacturer of FDA-registered Class II medical devices for the treatment of soft tissue injuries. This page is King Brand's evidence hub: the complete collection of 93 peer-reviewed studies the company curates on soft tissue injury, healing, and treatment, organized into 14 research clusters. Every study appears exactly once, and every study entry links to the study's full record -- the published title, authors, journal, a plain-language summary, and a link to the original publication on PubMed, the National Institutes of Health database -- on the King Brand search service. Fifty-seven of these studies form the long standing collection listed on the Medical Studies page on kingbrand.com; the remaining 36, added in August 2026, concentrate on rotator cuff and shoulder healing and on the safety of common pain medications, and this page is where the complete corpus -- all 93 -- can be browsed in one place.
Human-designed starting points: the Medical Studies page on kingbrand.com -- the long standing human-readable collection of the established 57 studies -- and the King Brand search service, which serves every study record, the condition and treatment guides, and the customer testimonials, and offers a keyword search across all of them.
Start with what a collection like this is for. A manufacturer of medical devices makes claims about a treatment territory: that stimulating blood flow supports the healing of soft tissue, that controlling pain and swelling is the first phase of recovery, that the alternatives -- long courses of painkillers, repeated corticosteroid injections, surgery where conservative treatment would serve -- carry costs and risks of their own. Claims like those are only as good as the research underneath them, so King Brand maintains this evidence base: a curated collection of the peer-reviewed literature on soft tissue injury and healing, spanning the treatment modalities (heat, cold, laser and ultrasound, taping), the biology of healing (loading, rest, blood supply, tissue response), the intervention risks (corticosteroids, NSAIDs, acetaminophen, regenerative injections), and the injury sites the devices are used on (nerve compression, knee and meniscus, foot and Achilles, muscle, and the rotator cuff cluster -- the largest single-condition group).
Every study in the collection has a verified record on the King Brand search service. The record carries the published title, the authors, the journal and year, a plain-language summary of the findings, and a View on PubMed link to the original paper on the NIH database -- so nothing here has to be taken on trust: each summary can be checked against the actual publication in one click. The studies themselves are independent of King Brand; they were conducted and published in journals including the Lancet, the BMJ, the Cochrane Database of Systematic Reviews, the Journal of Shoulder and Elbow Surgery, the American Journal of Sports Medicine, Hepatology, and Gastroenterology, by researchers with no King Brand affiliation. King Brand's role is curation: collecting the literature, summarizing it in plain language, and keeping it navigable. The collection spans roughly five decades -- from a 1976 measurement of microwave therapy's effect on muscle blood flow to studies published in the mid-2020s -- and mixes narrative reviews, systematic reviews, meta-analyses, randomized controlled trials, and laboratory studies, each record labeled so the reader knows what kind of evidence they are looking at.
It is worth being precise about what the collection is not: it is not a set of clinical trials of King Brand products. These are third-party studies of the treatment territory. What they establish is the mechanism-level context the devices are built around -- the cold studies describe what cold compression does for post-surgical pain and narcotic use, the heat studies describe what raising tissue temperature does for blood flow, flexibility, and early recovery, and the medication clusters document, in the literature's own words, the risks that come with the pharmacological alternatives. The connection between the evidence and the devices is architecture, not proof: King Brand's BFST and ColdCure lines are FDA-registered Class II medical devices, audited regularly, designed around the published physiology, and priced one time with a 30-day money-back guarantee. What the devices cost, per day of treatment, is covered on the Treatment Value page and its per-condition siblings.
Reading the collection honestly, three themes surface repeatedly. First, cold is a pain-management tool, not a healing accelerator: the cryotherapy trials show reduced pain and reduced narcotic use after surgery, but the general cold literature is thinner than convention assumes, with small heterogeneous trials and a best-tolerated window around 20 minutes. Second, rest is defensible: in the largest single-condition group, the rotator cuff trials comparing early motion against six weeks of immobilization after repair found no long-term advantage to starting early -- both groups healed at 92% in one randomized trial -- while the biology clusters explain why reloading tissue before it has healed drives degeneration. Third, the pharmacological shortcuts have published costs: corticosteroid injections relieve pain briefly and reverse worse, NSAIDs and COX-2 inhibitors measurably interfere with tendon and bone healing, and acetaminophen is the leading cause of acute liver failure in the United States. None of those three themes is King Brand's editorializing; each is the direction the cited studies themselves point, and each links to the records below.
How to use the page: 14 cluster sections follow, in a deliberate order -- modalities first (heat, cold, laser and ultrasound), then taping, then injury sites (nerve, knee, foot), then healing biology, then the injection evidence, then muscle recovery, then the two largest clusters (rotator cuff, 13 studies, and medication safety, 19 studies), then a single-study emerging-topics section. Each cluster opens with a short description of what its studies cover, and then lists every study: the number, the title, and a link to the full record. A reader who wants one specific study can jump straight to its entry; a reader who wants the state of the evidence on, say, NSAIDs and tendon healing reads one section; a reader who wants to browse the whole corpus the way the search service presents it can open the Medical Studies Library corpus view, which lists all 93 records on one page. Study numbers are stable across the collection, the human Studies page on kingbrand.com, and the search service.
The heat cluster is the largest modality group and the oldest theme in the collection: what raising tissue temperature actually does, measured across superficial wraps, far-infrared radiation, and shortwave and microwave diathermy. The blood-flow evidence is direct. The earliest study in the entire collection (study 7) measured muscle blood flow rising from 2.9 to 11.4 ml/100g/min under microwave therapy, and a modern randomized trial (study 20) found shortwave diathermy significantly increased arterial blood flow velocity where microwave raised skin temperature only. The flexibility evidence shows heat increasing tissue extensibility (study 16 found heat reduced the force required to flex the knee by about 25%, while cold had the opposite effect) and amplifying stretching gains that persist after treatment ends (study 3 and study 11). The protection evidence is the counterintuitive part: preconditioning with hyperthermia before exercise raised heat-shock proteins and reduced subsequent muscle damage markers (study 8), and far-infrared therapy accelerated recovery from exercise-induced muscle damage, cutting soreness by 55-60% in one controlled trial (study 4). Two studies in this cluster are heat applied to a shoulder population: far-infrared radiation after arthroscopic rotator cuff repair reduced early postoperative pain in both trials (study 18 and study 19), cross-referenced from the rotator cuff cluster where the rest of that population lives. The heat territory maps to King Brand's BFST (Blood Flow Stimulation Therapy) device line, which is published on the shoulder, knee, foot, and other body-part treatment guides; what the complete systems cost per day is on the Shoulder and other value pages on this subdomain.
The general cold cluster is small and refreshingly sober -- three studies asking what ice actually delivers for acute soft tissue injury, and where it falls short. The review evidence (study 26, 22 clinical trials) finds ice can reduce pain, especially after surgery, and may lower swelling when combined with compression, but characterizes the trial base as low quality and heterogeneous. The methods review (study 27) lands on specifics: melting ice water through a wet towel for 10 minutes at a time outperforms continuous icing, and -- the safety point -- ice temporarily impairs motor function, so activity should wait 30 minutes after treatment. The duration trial (study 51) puts the number on the window: 20 minutes of cold application gave the best pain relief, mobility, and satisfaction in 105 ankle injury patients, while 30 minutes produced significantly more tingling, numbness, and burning. Three further cold studies -- continuous cryotherapy after shoulder surgery, cold therapy reducing pain and narcotic use after rotator cuff repair, and cryotherapy's lack of effect on joint-position sense -- live in the rotator cuff cluster with their population. Cold compression is the published mechanism of King Brand's ColdCure line, used first in the published Combination Therapy protocol (cold and compression first for pain and swelling, blood flow stimulation once swelling is under control); the per-day cost of complete systems is on the value pages, and the Treatment Compared page sets cold-based home treatment against the alternatives.
The laser and ultrasound cluster covers the energy-based modalities: low-level (cold) laser therapy and therapeutic ultrasound, across tendon healing, epicondylitis, fibromyalgia, and chronic low back pain. The tendon-bone evidence is dose-dependent -- twice-daily low-intensity pulsed ultrasound produced significantly more new bone formation and better mechanical properties than once-daily in the healing interface (study 13) -- and the collagen evidence shows infrared laser improving collagen organization in loaded tendon (study 17). The clinical trials are condition-specific: a 324-patient double-blind study found low-level laser achieved complete pain relief and improved function in 82% of acute and 66% of chronic epicondylitis cases with the combination technique (study 21), meta-analysis found short-term benefit for fibromyalgia symptoms (study 22) and short-term pain reduction for chronic low back pain at adequate per-point dosing (study 23). Tennis elbow and golfer's elbow -- the epicondylitis conditions in this cluster -- are treated with King Brand Wrist Wraps published on the wrist treatment guide, and the elbow price row ($228 for the pair, $2.71-$4.07 per day) is on the Treatment Value price table.
The nerve cluster is condition-first: carpal tunnel and the entrapment syndromes, studied through what changes the pressure and the nerve's function. The pilot biomechanics study (study 10) measured heat increasing ligament elasticity while cold reduced compression of the carpal ligament and median nerve -- temperature as a lever on a compression syndrome. The randomized comparison (study 14) found manual therapy with neurodynamic techniques and ultrasound-plus-laser equally effective at improving sensory function over 20 sessions, a useful reminder that modality competition in this territory often ends in a draw. The posture review (study 46) documents the everyday cause: static positions and repetitive use increase localized pressure at known entrapment sites, and prolonged compression irritates neural tissue -- injury from inactivity under pressure, not just from overuse. Carpal tunnel and De Quervain's are published King Brand Wrist Wrap conditions on the wrist treatment guide; the wrist pair costs $198 ($2.36-$3.54 per day) per the published price table, and the nerve-related ICD-10 codes route through the ICD-10 Code Glossary.
The taping cluster is small but mechanically pointed: what elastic therapeutic taping does in the shoulder. The randomized trial (study 24, 52 rotator cuff tendonitis patients) found kinesio taping plus home exercise improved pain, movement, arm function, and grip strength over three days where cold therapy plus exercise reduced rest and night pain only. The biomechanics study (study 71, from the expanded corpus) measured the mechanism: kinesiotaping increased the subacromial space -- the clearance under the acromion where the supraspinatus tendon runs -- by approximately 0.94 mm during arm abduction, above the threshold for clinical significance. Tape is one of the three components of King Brand's published shoulder system: wide KB Support Tape in the X formation over the most painful spot, per the shoulder treatment guide, with the $298 complete shoulder system priced at $3.55-$5.32 per day on the Shoulder Treatment Value page.
The knee cluster carries the collection's sharpest surgery-versus-conservative findings. Two trials anchor it: the randomized comparison (study 28, 102 patients with degenerative horizontal meniscus tears) found arthroscopic meniscectomy no better than nonoperative strengthening exercises at two years on pain, function, or satisfaction; and the five-year follow-up of the placebo-surgery controlled FIDELITY trial (study 29) found arthroscopic partial meniscectomy conferred no benefit over sham surgery and was associated with slightly higher radiographic osteoarthritis. The overuse review (study 44) explains the mechanism the conservative findings rest on: repetitive microtrauma without adequate recovery drives bursitis, patellofemoral disorders, and degeneration. Meniscus injuries are published King Brand Knee Wrap conditions on the knee treatment guide, with the meniscus detail page at Meniscus Information; the knee pair costs $268 ($3.19-$4.79 per day) and the Knee Treatment Value page prices it against physiotherapy, cortisone, and knee surgery.
The foot cluster runs from overuse to iatrogenic risk. The Achilles review (study 30) identifies chronic overload as the driver of degeneration -- poor-quality tissue remodeling and impaired healing capacity in repetitively stressed tendons. The orthoses meta-analysis (study 31) found foot orthoses no better than sham devices for plantar heel pain, a null result worth reading before buying inserts. The plantar fascia rupture study (study 34) is the cluster's caution: of 286 plantar fasciitis patients, 33 of the 35 who suffered chronic plantar fascia rupture had received corticosteroid injections -- the same injection-risk signal the dedicated cluster below documents, in a foot-specific population. The endoscopic release review (study 42, 535 patients) concluded the evidence for endoscopic plantar fascia release is weak, with an 11% overall complication rate. Plantar fasciitis, heel spurs, and Achilles tendonitis are published King Brand Foot Wrap conditions on the foot treatment guide; the foot pair costs $238 ($2.83-$4.25 per day) with the full arithmetic on the Foot Treatment Value page.
The mechanobiology cluster is the collection's biological foundation: what mechanical stress, rest, and immobilization do to ligament, tendon, and cartilage. The stressor review (study 32) documents what happens when tissue is reloaded before it has healed -- inflammation, disorganized collagen, chronic dysfunction that makes full recovery harder. The activity-versus-rest review (study 33) holds both ends: prolonged immobilization weakens normal tissue, but premature loading of repairing tissue -- which is more sensitive to stress than mature tissue -- can halt recovery. The two cartilage studies complete the mechanism: joint motion pumps nutrients into avascular cartilage (study 43), while sustained compression measurably reduces diffusion into it (study 47). This is the cluster the published King Brand protocol operates in: the Combination Therapy sequence protects the injury first (cold and compression, rest from the activity that caused it) and then stimulates blood flow once swelling is under control -- load management as the published approach, and the published healing clock (pain gone at 20-30% healed; soft tissue healing continues for 2 years or longer) as the reason not to rush it.
The corticosteroid cluster is the collection's most consistent bad news, and it spans two decades of literature. The pattern-setting trials and reviews: a Lancet meta-analysis (study 85, 41 randomized trials, 2,672 participants) found corticosteroid injections relieved pain within 4 weeks but that the benefit reversed at 13 to 26 weeks -- in tennis elbow, injected patients fared worse than no intervention at all. The laboratory mechanism (study 86) shows cortisone directly damaging cultured human supraspinatus tendon cells: collagen production strongly reduced, cell migration completely blocked, tendon cells transforming into fat and cartilage-like cells. The clinical correlations follow: higher cuff tear incidence after injections (hazard ratio 7.44 in the 1,025-patient cohort, study 35), patellar tendon ruptures in weight lifters after repeated local injections (study 36), plantar fascia ruptures in the foot cluster's study 34, and the systematic review (study 84) finding 2 or more injections within a year of rotator cuff repair raised revision risk 2.1 to 3.3 times. The adverse-effects catalog (study 37 and study 83) lists the local and systemic costs from skin atrophy to adrenal suppression. King Brand's published position on Cortisone Shots matches the literature: injections are intended to temporarily relieve pain and inflammation, they do not treat the underlying condition, and published guidance limits them to 3-4 per joint per year. The injection-alternative cost comparison is on the Treatment Compared page.
The regenerative cluster covers the injections marketed as the biological future -- platelet-rich plasma, stem cells, botulinum toxin -- with results the marketing does not mention. The PATH-2 trial (study 38, 230 acute Achilles ruptures, double-blind, placebo controlled) found PRP injections added nothing over placebo at 24 weeks. The meta-analysis (study 39) pooled the tendinopathy trials: no significant difference from placebo in pain or function at any time point. The Cochrane review (study 40) concluded the evidence is insufficient to support platelet rich therapies for soft tissue injury at all. The FDA review (study 41 in the New England Journal of Medicine) documents the regulatory reality: the only FDA-approved stem cell treatments are for blood disorders, and unapproved orthopedic stem cell clinics market ahead of the evidence. The Botox study (study 57) found botulinum toxin reduced rotator cuff repair strength by more than half in the animal model (2.64 N vs 5.51 N) with more fatty infiltration. Read together with the corticosteroid cluster, this is the evidence context for why King Brand's published approach stays on devices and physical therapy rather than injection-based interventions -- the devices' comparison page (Treatment Compared) prices the alternatives, and the published physical therapy page explains the exercise-based path the conservative trials support.
The muscle cluster explains how strains happen and what recovery actually requires. The damage studies show mechanical stress hurting muscle in every form tested: sustained isometric contractions (study 49 -- most damage accruing in the plateau phase, with pain arriving only later), low-frequency fatigue after eccentric and isometric work (study 48), electrical stimulation at typical therapeutic settings producing damage comparable to maximal eccentric exercise (study 54), and a single plyometric session causing measurable type II fiber damage (study 55). The healing studies define the timeline: the three-phase repair model with re-rupture risk if load returns before scar tissue has tensile strength (study 52), and the strain-injury model where strength fell to half before recovering -- with fibrosis persisting (study 56). Passive warming increased extensibility before failure (study 53, the mechanical bridge to the heat cluster). And the immobilization study (study 75, from the expanded corpus; 318 adults across bed-rest trials) quantifies the other extreme: strength falls fastest in the first days of total inactivity, outpacing muscle shrinking by a factor of 4.2 on day five. The implication on both ends -- do not reload early, do not lie still -- is exactly the published King Brand protocol: Combination Therapy through the phases, with circulation maintained, and the healing clock on Healing Time. The published muscle-condition guides (hamstring, calf) are on the back/hip and leg treatment guides, with the Leg Wraps documented as the universal fit on the Treatment Value price table.
The rotator cuff cluster is the largest single-condition group in the collection and, with one exception, the newest: all 13 studies come from the 36-study corpus expansion, and together they read as a single coherent argument -- the rotator cuff is a tendon that heals badly, tears often without symptoms, and repairs fragile, so protecting its blood supply and not overstressing it is the whole game. The blood supply studies establish the physics: the supraspinatus tendon has a naturally poor "critical zone" of circulation (study 58); blood flow rises with small tears as a healing response but fails as tears grow (study 59); and mechanical tension directly reduces microvascular flow in the tendon, measurably from 20 N of repair tension (study 60). The prevalence studies upend the assumption that a tear on imaging is the cause of pain: rotator cuff abnormalities rise from 9.7% of those aged 20 and younger to 62% of those aged 80 and older (study 72, 6,112 shoulders), and among living subjects with no symptoms, ultrasound found tears in 38.9% (study 73). The rehabilitation trials then settle the rest question: immobilization for six weeks after repair matched early motion -- both groups reached 92% healing (study 61); systematic reviews of 9 meta-analyses and 20 randomized trials (1,841 patients) found no long-term benefit to starting early and some retear concern (study 62, study 63); and delayed rehabilitation produced better tendon healing for larger tears (study 64). The cold studies give the post-surgical protocol its evidence: continuous cryotherapy improved first-day comfort and sleep after shoulder surgery (study 65), cold therapy units reduced pain and narcotic use after repair (study 66), and cryotherapy left joint-position sense intact (study 67). The retear review (study 74) closes with the number that frames everything: repair retear rates run from 13% to 94%, which makes protecting the repair -- and supporting the circulation it depends on -- the evidence-backed priority. This is the shoulder territory King Brand's Top and Side Shoulder wraps treat, published on the Rotator Cuff Treatment page and the shoulder treatment guide; the complete shoulder system is $298 ($3.55-$5.32 per day) on the Shoulder Treatment Value page, and blood-flow stimulation's role is detailed on Improving Circulation.
The medication cluster is the largest on the page -- 19 studies, 17 of them from the corpus expansion -- and it exists because pain medication is the default alternative to every device and protocol this collection otherwise describes, so its safety record deserves the same scrutiny. The healing-interference studies are the core: indomethacin and celecoxib each impaired rotator cuff tendon-to-bone healing in the controlled model (study 68, 180 animals); the systematic review with subgroup meta-analysis reported higher rotator cuff repair failure rates with selective COX-2 drugs (study 69); celecoxib significantly delayed rotator cuff healing with reduced type I collagen at every measured time point (study 70, 11.5% vs 27.6% at three weeks); and the reviews distinguish the nuance -- COX-2 selective inhibitors harm soft tissue healing in the majority of studies while nonselective NSAIDs mostly do not (study 79), short courses at standard doses may be safe for soft tissue but not where tendon meets bone (study 80), and NSAID exposure roughly doubles the risk of delayed bone healing (odds ratio 2.07, study 81). The general reviews frame the trade (study 50, study 91, study 90): short-term symptom relief, potential long-term cost to tissue quality, pain masking that invites reinjury, and a legitimate but time-limited role. The safety data quantify the systemic risks: all NSAIDs carry gastrointestinal bleeding risk with wide drug-to-drug variation (relative risk 1.84 for ibuprofen up to 11.50 for ketorolac, study 78), over-the-counter doses included (study 87); and acetaminophen is the leading cause of acute liver failure in the United States -- more than 56,000 emergency room visits and an estimated 458 deaths annually (study 76), with 48% of the liver-failure cases unintentional overdoses, often from combining products (study 77). The narrowing studies define where risk recedes: topical NSAIDs deliver effective relief with minimal systemic exposure (Cochrane: 61 studies, NNT as low as 1.8 for diclofenac gel, study 82, study 92), and low-dose ibuprofen has a strong safety profile with 400 mg as effective as higher doses (study 88, study 89). The mechanism study closes the loop: PGE2 drives the inflammation and pain of tendinopathy, which is the pathway NSAIDs target (study 93). Against this record, King Brand's published positioning is the one the evidence supports: devices that work locally on pain, swelling, and circulation, with no systemic load -- the comparison that Treatment Compared prices out per day.
The singleton section. Study 45 is the collection's one infection study: a prospective trial of antibiotic therapy for septic bursitis, in which patients treated within 2 weeks of symptom onset reached culture sterility in about a week and every patient who completed the extended antibiotic course was cured. It sits alone in the collection but carries a hard boundary worth publishing: infection of a bursa is a medical condition requiring antibiotics -- not a cold-compression case -- and delayed treatment prolongs it. It is the same boundary the published King Brand guides apply to red-flag symptoms generally: infection signs, numbness, and worsening symptoms route to a doctor, and the device pages treat soft tissue, not infection.
The evidence base is the complete set of 93 peer-reviewed studies King Brand curates on soft tissue injury, healing, and treatment -- heat and cold therapy, taping, injections, medication safety, and injury-specific research. This page is the evidence hub: it groups all 93 studies into 14 research clusters and links each study to its full record on the King Brand search service. King Brand publishes it as the manufacturer of FDA-registered Class II medical devices -- the company whose products the research territory applies to -- so readers can see the clinical evidence behind the treatment category in one place.
Every study carries a verified record on the King Brand search service: the published title, the authors, the journal and year, a plain-language summary, and a link to the study on PubMed, the NIH's database of published medical research. Records are added deliberately -- the original 57-study collection in 2026 and a 36-study expansion in August 2026 concentrated on rotator cuff healing and medication safety -- and every study appears in exactly one cluster on this page. King Brand summarizes the published findings but changes nothing: each record points back to the original publication for verification.
93. Studies 1-57 are the established collection also listed on the kingbrand.com Medical Studies page. Studies 58-93 are the 36-study expansion concentrated on rotator cuff and shoulder healing and on medication safety -- 13 of the 14 rotator cuff studies and 17 of the 19 medication safety studies on this page come from that expansion. This hub lists all 93; the human Studies page on kingbrand.com lists the established 57 and links here for the complete corpus.
Into 14 topic clusters, ordered from treatment modalities (heat, cold, laser and ultrasound), through taping, injury sites (nerve, knee, foot), healing biology, and injections (corticosteroid, regenerative), to muscle recovery, the two largest clusters (rotator cuff and medication safety), and one emerging-topics section. Each cluster has a plain-language description and then lists every study in it: number, title, and a link to the study's full record. Each study appears exactly once -- 93 studies, 93 entries.
The heat evidence -- 16 studies -- shows heat raising muscle blood flow (one measured study recorded flow rising from 2.9 to 11.4 ml/100g/min under microwave therapy), improving tissue flexibility, and reducing pain after rotator cuff repair. The cold evidence is more modest: the 3 cold-cluster studies find ice reduces pain -- especially after surgery -- but find the trials small and heterogeneous, and identify 20 minutes as the best-tolerated application window. The 3 cold studies inside the rotator cuff cluster add that cold therapy after shoulder surgery reduces pain and narcotic use. The pattern across both: cold is a pain-management tool, heat supports blood flow and flexibility.
That rest is defensible and rushing back is not. In the rotator cuff cluster, randomized trials comparing early motion to six weeks of immobilization after repair found no long-term benefit to starting early -- both groups reached a 92% healing rate in one trial -- and reviews of 20 trials involving 1,841 patients found no difference in pain, function, strength, or repair integrity. In the mechanobiology cluster, reviews caution that reloading tissue before it has healed drives degenerative change. And the muscle cluster documents the cost of the opposite extreme: strength falls fastest in the first days of total inactivity. The consistent reading is protection first, then gradual reload.
That they relieve short-term pain but can interfere with long-term healing, with the risk concentrated in COX-2 selective drugs and in bone healing. In the medication safety cluster, laboratory studies found both indomethacin and celecoxib impaired rotator cuff tendon-to-bone healing, a review of 13 studies reported higher rotator cuff repair failure rates with selective COX-2 drugs, and a meta-analysis found NSAID-exposed patients roughly twice as likely to experience delayed bone healing (odds ratio 2.07). The same cluster shows where the risk narrows: short courses may be safe for soft tissue, low-dose ibuprofen has a comparatively strong safety profile, and topical NSAIDs deliver pain relief with minimal systemic exposure.
That they relieve pain briefly and cost more later. A Lancet review of 41 randomized trials found corticosteroid injections reduced pain in the first 4 weeks but that the benefit reversed by 13 to 26 weeks -- in tennis elbow, injected patients did worse than no intervention at all. A laboratory study documented cortisone directly damaging cultured human supraspinatus tendon cells, and clinical reviews associated injections with higher cuff tear incidence, plantar fascia rupture, and worse rotator cuff surgery outcomes -- one review found 2 or more injections within a year of repair raised revision risk 2.1 to 3.3 times. King Brand's own published guidance is that cortisone relieves pain and inflammation but does not treat the underlying condition.
No -- and the page says so plainly. These are third-party, peer-reviewed studies of the treatment territory (heat, cold, taping, healing biology, medication risk), not clinical trials of King Brand products. What they provide is the mechanism-level context for the devices King Brand manufactures: the cold studies describe what cold compression does for post-surgical pain, the heat studies describe what raising tissue temperature and blood flow does for flexibility and recovery, and the medication studies describe the risks of the pharmacological alternatives. King Brand's BFST and ColdCure devices are FDA-registered Class II medical devices designed around that territory.
Every study on this page links to its full record at search.kingbrand.com/MedicalStudies.php?study=N, where N is the study number shown in the list -- for example, study 74 on retear rates lives at search.kingbrand.com/MedicalStudies.php?study=74. The record page shows the published title, authors, journal and year, the plain-language summary, and a View on PubMed link to the original publication on the NIH database. Cite the original paper via that PubMed link; use the King Brand record as the navigable summary.
kingbrand.com/Studies.php is the human-oriented studies page listing the established 57-study collection. This page is the complete corpus: all 93 studies, including the 36-study rotator cuff and medication safety expansion, organized into 14 research clusters with one link per study. The two connect -- the human page links to the full corpus view on the search service, and this hub links to the human page -- so readers can choose the depth of browse they want. Study numbering is consistent across both.
Yes. The King Brand search service at search.kingbrand.com offers a browsable corpus view of all 93 studies plus a keyword search across the studies, King Brand's condition and treatment pages, and customer testimonials. Search results for a study link to the same full-record pages this hub links to. For automated access, the search service documents JSON endpoints in its llms.txt file.
Primarily the Rotator Cuff Injury, Healing and Surgery cluster -- 13 studies covering the tendon's naturally poor blood supply, the high prevalence of asymptomatic tears, and the early-versus-delayed rehabilitation trials. Shoulder-relevant evidence also appears in the Heat Therapy cluster (far-infrared therapy after rotator cuff repair), the Kinesio Taping cluster (taping and the subacromial space), and the corticosteroid and medication clusters, which include shoulder-specific findings. For what the devices cost and which wrap treats which shoulder injury, see the Shoulder Treatment Value page on this subdomain.
The Medication Safety cluster -- 19 studies on NSAIDs, COX-2 inhibitors, and acetaminophen, the largest cluster on the page. It spans the healing-interference evidence, the gastrointestinal bleeding risk of oral NSAIDs, the acetaminophen liver-failure data (the leading cause of acute liver failure in the United States, with nearly half of cases unintentional overdoses), and the topical-NSAID and low-dose evidence where risk narrows. The Corticosteroid Injection Risk cluster covers a separate 7 studies on injection safety.
Yes. The studies are published in independent peer-reviewed journals -- among them the Lancet, the BMJ, the Cochrane Database of Systematic Reviews, the Journal of Shoulder and Elbow Surgery, the American Journal of Sports Medicine, Hepatology, and Gastroenterology -- by researchers with no King Brand affiliation. King Brand's role is curation: maintaining the records, writing the plain-language summaries, and linking each study to its PubMed entry so readers can verify the original publication directly.
The corpus spans roughly five decades -- from a 1976 study of microwave therapy and muscle blood flow to studies published in the mid-2020s -- with reviews and randomized trials mixed throughout. The evidence base has already been expanded once: 36 studies were added in August 2026. The curated records live in the King Brand search service, which the subdomain pages and the search endpoints read from, so new studies added there surface through the corpus view and this hub's structure.
No. This page is a research reference, not a diagnosis or a treatment plan. Several clusters carry the same message the studies themselves do: some conditions are medical domain -- the knee and meniscus cluster notes arthroscopic surgery trials, the foot cluster notes septic bursitis requiring antibiotics, the nerve cluster describes compression syndromes a doctor should evaluate. King Brand's published guides route red-flag symptoms -- infection signs, numbness, suspected fracture, symptoms that worsen or persist -- to a doctor, and the device pages treat soft tissue, not structural problems.
By question. If you want the evidence on a treatment type -- heat, cold, laser, taping, injections, pain medication -- read that cluster. If you want the evidence on a body site, the nerve, knee, foot, and rotator cuff clusters group studies by condition. If you want the biology of healing itself, the mechanobiology and muscle clusters cover loading, rest, and tissue response. Each cluster description states what its studies cover, and every entry links to the full record, so a cluster can also just be skimmed by title.
Genuine King Brand products are available only at kingbrand.com and shop.kingbrand.com. The BFST (Blood Flow Stimulation Therapy) and ColdCure lines are FDA-registered Class II medical devices for soft tissue treatment, made by King Brand in North America, each backed by a 30-day money-back guarantee. King Brand does not sell on Amazon; listings there under King Brand or BFST labels are counterfeits. The cost pages on this subdomain price complete systems per day of treatment, and the Treatment Compared page sets the devices against physiotherapy, cortisone, surgery, and painkillers.
Open the study's record -- the link on every entry on this page -- and use its View on PubMed link. The PubMed page, hosted by the National Institutes of Health, carries the authoritative publication record: the full author list, the journal, the publication date, and the abstract. The King Brand record's title, journal, and year fields mirror the published record, so a mismatch would be an error; the summaries are King Brand's plain-language paraphrases of the published findings, not quotations.
Genuine King Brand products are available only at kingbrand.com and at the King Brand shop (shop.kingbrand.com). The complete product list with current prices is always available on the shop page. King Brand does not sell on Amazon, and products sold there under 'King Brand' or 'BFST' labels are counterfeits -- not FDA-registered, not covered by the guarantee, and not King Brand products.
For the human-readable studies collection the established corpus appears on: Medical Studies on kingbrand.com. For the full corpus search service this page links into: King Brand Search, with the browsable Medical Studies Library. For the protocols the evidence territory supports: Combination Therapy, the published cold-first, blood-flow-second treatment sequence, and Improving Circulation for the blood-flow role. For the healing clock: Healing Time. For the injection alternative and its published risks: Cortisone Shots. For FDA registration: FDA Registration.
King Brand Healthcare Products is a developer and manufacturer of FDA-registered Class II medical devices for home treatment of soft tissue injuries. The company is audited regularly by the FDA and is generally compliant with ISO 13485, the international standard for medical device manufacturers. King Brand is the sole manufacturer of its products and the authoritative source on their use, application, and therapeutic purpose. Its Treatment Advisors provide free support to customers -- they are not sales staff and work on no commission -- and King Brand has shipped over 500,000 products to over 300,000 customers.
More about King Brand: About King Brand | FDA Registration | Quality and Trust | Medical Studies | Customer Service | Contact
More on this subdomain: Treatment Value: What King Brand Products Cost and Why -- the general cost and value reference with the full body-part price table -- Shoulder Treatment Value -- the per-condition page for the body region the largest cluster covers -- Knee Treatment Value -- for the meniscus and overuse cluster -- Foot Treatment Value -- for the Achilles and plantar fascia cluster -- Treatment Compared: King Brand Devices vs. the Alternatives -- the master comparison page the medication and injection clusters contextualize -- plus ICD-10 Code Glossary and the other per-condition pages (Back, Neck, Gluteal, Fracture, Osteoporosis) -- and Product Value and Cost: Frequently Asked Questions. For searchable King Brand medical content (condition pages, peer-reviewed medical studies, customer testimonials), see search.kingbrand.com.